Genmab — Oktober 2019

[E_L]

POMALYST/IMNOVID sales for the third quarter were $664 million, an increase of 29 percent year-over-year. U.S. sales were $469 million and international sales were $195 million, an increase of 31 percent and 25 percent year-over-year, respectively. POMALYST/IMNOVID sales growth was driven primarily by the adoption of triplet therapy for myeloma resulting in increases in treatment duration and market share.

[Solsen]

They are happy about the partner Daratumumab

[E_L]

[E_L]

for those that did not bother to read @gentogen 's link below, it clearly states "The ongoing combination trials in Multiple Myeloma and Lymphoma as well as combination trials with isatuximab and atezolizumab in solid tumors continue."

[Bella1]

Det lader til, at træet er ved at være rystet færdigt for denne gang

[E_L]

it is also end-of-month today, could see a good size auction

[E_L]

Horizon Therapeutics plc (Nasdaq: HZNP) today announced integrated, pooled efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab https://ir.horizontherapeutics.com/news-releases/news-release-details/integrated-clinical-trial-analyses-further-substantiate

[Helge_LarsenPI-redaktør]

Bella..En Genmab-Classic efterhånden.

[hspinvest]

Så gik GMAB i usa i Plus, mon ikke det sker med DK versionen også inden snart

[Helge_LarsenPI-redaktør]

Bingo

[bikube]

Hvis lukkeauktionen former sig som igår, så har vi da ikke noget at klage over.

[Helge_LarsenPI-redaktør]

Købssiden ser vild ud.

[Helge_LarsenPI-redaktør]

Lige før små 8.000 på 1.456,50

[Helge_LarsenPI-redaktør]

Nu 9443 på 1.456

[Helge_LarsenPI-redaktør]

8.700 på 1.458 ...Køberne er insisterende.

[Helge_LarsenPI-redaktør]

Auktion nu.

[Bulder]

Hvis gmab$ skal bestemme, så lukker vi i 1463

[Helge_LarsenPI-redaktør]

1.460 ...51.000 stk igennem til slut.

[Doublo]

blåt er nu altid pænt

[Bulder]

var da med til at trække pf i et kæmpe plus på 0,01%